Literature DB >> 1615498

The bleeding time in normal subjects is mainly determined by platelet von Willebrand factor and is independent from blood group.

F Rodeghiero1, G Castaman, M Ruggeri, A Tosetto.   

Abstract

Bleeding time (BT) is the most important test "in vivo" evaluating the primary hemostasis. No relationship between plasma von Willebrand factor (vWF) and BT has been found in normal subjects, whereas no data are available on the relationship between platelet vWF and blood group or BT in normal subjects. To clarify the reciprocal relationship between blood group, vWF and BT, we studied 177 normal subjects. The influence of blood group on BT was analyzed in 116 subjects and the distribution of platelet and plasma vWF between different blood groups in 111 subjects. Furthermore, in a subgroup of 50 subjects, a multivariate regression model, including age, platelet count, plasma and platelet vWF:Ag and Ristocetin Cofactor (RiCof), hematocrit, sex and O or non-O blood group was used to assess the joint influence of these variables on BT. BT was similar in O and non-O group (P = 0.310) and, although plasma vWF was significantly lower in O group (P less than 0.0001), platelet vWF content was similarly distributed (P = 0.873 vWF:Ag and P = 0.322 RiCof). Furthermore, platelet vWF was not correlated with plasma vWF (r = 0.06, P = 0.526). In the multivariate regression analysis, only platelet vWF, age and platelet count showed a significant, inverse correlation with BT (P = 0.004), explaining 25% of the total variation of this test. Platelet vWF resulted therefore the main determinant of BT.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615498     DOI: 10.1016/0049-3848(92)90210-2

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis.

Authors:  S Kanaji; S A Fahs; Q Shi; S L Haberichter; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

2.  Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels.

Authors:  Michelle Lavin; Sonia Aguila; Sonja Schneppenheim; Niall Dalton; Kenneth L Jones; Jamie M O'Sullivan; Niamh M O'Connell; Kevin Ryan; Barry White; Mary Byrne; Marie Rafferty; Mairead M Doyle; Margaret Nolan; Roger J S Preston; Ulrich Budde; Paula James; Jorge Di Paola; James S O'Donnell
Journal:  Blood       Date:  2017-09-15       Impact factor: 22.113

Review 3.  Platelet von Willebrand factor in inherited and acquired bleeding disorders.

Authors:  P M Mannucci
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

4.  A revised model of platelet aggregation.

Authors:  S Kulkarni; S M Dopheide; C L Yap; C Ravanat; M Freund; P Mangin; K A Heel; A Street; I S Harper; F Lanza; S P Jackson
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

5.  Determination of normal range of bleeding time in rural and urban residents of Borujerd, Iran: A pilot study.

Authors:  Ali Maleki; Hamidreza Roohafza; Negin Rashidi; Farshid Aliyari; Reza Ghanavati; Saeed Foroughi; Behjat Nabatchi; Maria Torkashvand
Journal:  ARYA Atheroscler       Date:  2012

6.  Quantitative 3D microscopy highlights altered von Willebrand factor α-granule storage in patients with von Willebrand disease with distinct pathogenic mechanisms.

Authors:  Maurice Swinkels; Ferdows Atiq; Petra E Bürgisser; Johan A Slotman; Adriaan B Houtsmuller; Cilia de Heus; Judith Klumperman; Frank W G Leebeek; Jan Voorberg; Arend Jan Gerard Jansen; Ruben Bierings
Journal:  Res Pract Thromb Haemost       Date:  2021-09-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.